Compare ADVB & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADVB | TCRT |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 7.8M |
| IPO Year | 2023 | 2025 |
| Metric | ADVB | TCRT |
|---|---|---|
| Price | $3.22 | $2.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.1K | ★ 12.6M |
| Earning Date | 10-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3431.25 | 24.66 |
| EPS | ★ 5.33 | N/A |
| Revenue | $127,637.00 | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $0.72 |
| 52 Week High | $113.80 | $4.50 |
| Indicator | ADVB | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 21.55 | 54.66 |
| Support Level | N/A | $1.50 |
| Resistance Level | $5.59 | $2.54 |
| Average True Range (ATR) | 0.55 | 0.71 |
| MACD | -0.16 | 0.15 |
| Stochastic Oscillator | 5.01 | 41.73 |
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.